CW
VKTX icon

Channel Wealth’s Viking Therapeutics VKTX Stock Holding History

Channel Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Sell
50,028
-47,929
-49% -$1.55M 0.44% 58
2026
Q1 		$3.19M Buy
97,957
+22,482
+30% +$723K 0.77% 47
2025
Q4 		$2.66M Buy
+75,475
New +$2.67M 0.67% 50

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Channel Wealth's VKTX Position: Q2 2026 in Review

Channel Wealth reduced its Viking Therapeutics (VKTX) stake by 49% in Q2 2026, selling an estimated $1.55M and leaving 50,028 shares worth $1.95M. The position accounts for 0.44% of the portfolio, ranked #58.

Channel Wealth first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.19M in Q1 2026. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Channel Wealth held 50,028 shares of Viking Therapeutics worth $1.95M as of Q2 2026.
  • Channel Wealth sold 47,929 Viking Therapeutics shares in Q2 2026, an estimated $1.55M.
  • Viking Therapeutics made up 0.44% of Channel Wealth's portfolio in Q2 2026, its #58 holding.
  • Channel Wealth first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Channel Wealth's Viking Therapeutics position peaked at $3.19M in Q1 2026.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Channel Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.